136 related articles for article (PubMed ID: 29018161)
1. High prevalence of the
Vos JM; Notermans NC; D'Sa S; Lunn MP; van der Pol WL; Kraan W; Reilly MM; Chalker J; Gupta R; Kersten MJ; Pals ST; Minnema MC
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):1007-1009. PubMed ID: 29018161
[No Abstract] [Full Text] [Related]
2. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract][Full Text] [Related]
3.
Allain JS; Thonier F; Pihan M; Boulland ML; de Guibert S; Launay V; Doncker AV; Ganard M; Aliouat A; Pangault C; Houot R; De Tayrac M; Lamy T; Roussel M; Fest T; Decaux O; Pastoret C
Haematologica; 2018 May; 103(5):e207-e210. PubMed ID: 29371323
[No Abstract] [Full Text] [Related]
4. [Neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein (MAG) antibody].
Kawagashira Y; Koike H; Sobue G
Nihon Rinsho; 2015 Sep; 73 Suppl 7():440-5. PubMed ID: 26480739
[No Abstract] [Full Text] [Related]
5. Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2003; (1):CD002827. PubMed ID: 12535440
[TBL] [Abstract][Full Text] [Related]
6. [Anti-Myelin-associated Glycoprotein Neuropathy].
Kuwahara M
Brain Nerve; 2024 May; 76(5):540-546. PubMed ID: 38741494
[TBL] [Abstract][Full Text] [Related]
7. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
Gomez A; Hoffman JE
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
[No Abstract] [Full Text] [Related]
8. Association of variability in antibody binding affinity with a clinical course of anti-MAG neuropathy.
Matsui T; Hamada Y; Kuwahara M; Morise J; Oka S; Kaida K; Kusunoki S
J Neuroimmunol; 2020 Feb; 339():577127. PubMed ID: 31841738
[TBL] [Abstract][Full Text] [Related]
9. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35577568
[TBL] [Abstract][Full Text] [Related]
10. Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test?
Giannotta C; Di Pietro D; Gallia F; Nobile-Orazio E
Eur J Neurol; 2015 May; 22(5):879-82. PubMed ID: 25597226
[TBL] [Abstract][Full Text] [Related]
11. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35798560
[TBL] [Abstract][Full Text] [Related]
12. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
13. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies.
Erb S; Ferracin F; Fuhr P; Rösler KM; Hess CW; Kuntzer T; Bogousslavsky J; Sztajzel R; Steck AJ
J Neurol; 2000 Oct; 247(10):767-72. PubMed ID: 11127531
[TBL] [Abstract][Full Text] [Related]
14. [Anti-MAG antibody associated neuropathy].
Ogino M; Saito T
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):487-91. PubMed ID: 10434706
[No Abstract] [Full Text] [Related]
15. Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy.
Gabriel JM; Erne B; Bernasconi L; Tosi C; Probst A; Landmann L; Steck AJ
Acta Neuropathol; 1998 May; 95(5):540-6. PubMed ID: 9600601
[TBL] [Abstract][Full Text] [Related]
16. Anti-myelin-associated glycoprotein neuropathy.
Steck AJ; Stalder AK; Renaud S
Curr Opin Neurol; 2006 Oct; 19(5):458-63. PubMed ID: 16969155
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with neuropathy and anti-MAG IgM M-proteins.
Nobile-Orazio E; Baldini L; Barbieri S; Marmiroli P; Spagnol G; Francomano E; Scarlato G
Ann Neurol; 1988 Jul; 24(1):93-7. PubMed ID: 2458065
[TBL] [Abstract][Full Text] [Related]
18. Correlation between cytomegalovirus infection and IgM anti-MAG/SGPG antibody-associated neuropathy.
Yuki N; Yamamoto T; Hirata K
Ann Neurol; 1998 Sep; 44(3):408-10. PubMed ID: 9749612
[TBL] [Abstract][Full Text] [Related]
19. The role of human natural killer-1 (HNK-1) carbohydrate in neuronal plasticity and disease.
Morise J; Takematsu H; Oka S
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2455-2461. PubMed ID: 28709864
[TBL] [Abstract][Full Text] [Related]
20. Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies.
Boso F; Ruggero S; Giannotta C; Benedetti L; Marfia GA; Ermani M; Campagnolo M; Salvalaggio A; Gallia F; De Michelis C; Visentin A; Bianco M; Ruiz M; Mataluni G; Nobile-Orazio E; Briani C
Eur J Neurol; 2017 Nov; 24(11):1334-1340. PubMed ID: 28782863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
